[Impact of TP53 and MYD88 Mutations on Treatment Efficacy in Diffuse Large B-Cell Lymphoma]
{{output}}
Objective: To investigate the relationship between TP53 and MYD88 mutations and treatment efficacy in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based standard chemoimmunotherapy. ... ...
